Pharma BD Deal Intelligence
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people…
Pharmalittle: We're reading about a Roche deal for an obesity drug, a Gilead HIV drug and more. Roche is paying $1.65 billion upfront to license amylin analog…
New data from the Phase 2 ZUPREME-1 trial presented at the American Diabetes Association 2026 Scientific Sessions further support petrelintide's…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Roche partnered with Zealand Pharma to co-develop petrelintide, an amylin analog for obesity, paying $1.65B upfront in a deal worth up to $5.3B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Zealand Pharma A/S (this deal) | 2025 | $5.3B | 63 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2025 deals · Roche Holding AG deals · Metabolic deals